Market Overview

Bank Of America Upgrades BioCryst As Financing Overhang Lifts Partially

Share:
Bank Of America Upgrades BioCryst As Financing Overhang Lifts Partially

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) completed a $55 million equity raise earlier this week.

While further financing may be needed to make the company launch ready, the recent equity raise has provided “some cushion,” according to Bank of America.

The Analyst

BofA’s Tazeen Ahmad upgraded BioCryst Pharmaceuticals from Neutral to Buy, while lowering the price target from $5 to $4.

The Thesis

Doctor checks conducted after the release of pivotal ApeX-2 study results in hereditary angioedema (HAE) had indicated interest in BioCryst Pharma’s ‘7353, given the convenience of its oral dosing, Ahmad said in the upgrade note.

The analyst continued to estimate unrisk-adjusted peak sales of $601 million in 2027 for ‘7353 in prophylactic HAE. He added that the US price of the treatment is estimated at around $400,000 per patient per year, after assuming a discount to competition.

The New Drug Application (NDA) filing of ‘7353 in prophylactic HAE with the European Union this quarter and Japan submission in the first quarter of 2020 are likely to be key near-term catalysts for the stock, Ahmad said.

He mentioned other near-term catalysts for the stock as the Phase III trial for ‘7353 in acute HAE beginning in 2020 and proof-of-concept data in paroxysmal nocturnal hemoglobinuria (PNH) from ongoing ‘9930 study in the first half of 2020.

Price Action

Shares of BioCryst Pharma were up 13.56% to $1.80 at the time of publishing on Friday.

Latest Ratings for BCRX

DateFirmActionFromTo
Nov 2019UpgradesNeutralBuy
May 2019DowngradesOutperformSector Perform
Apr 2019MaintainsEqual-WeightEqual-Weight

View More Analyst Ratings for BCRX
View the Latest Analyst Ratings

Posted-In: Bank of America Merrill Lynch Tazeen AhmadAnalyst Color Biotech Upgrades Price Target Analyst Ratings General

 

Related Articles (BCRX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
TOLGoldman SachsInitiates Coverage On42.0
KBHGoldman SachsInitiates Coverage On36.0
YEXTSunTrust Robinson HumphreyMaintains28.0
LHCGSunTrust Robinson HumphreyMaintains160.0
DLRSunTrust Robinson HumphreyMaintains140.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

McDonald's New McFlurry Will Hit Stores Soon

ORO Combines Machine Learning And Actual Feedback To Help You Find The Best CBD Products